| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| EXELExelixis, Inc. | 11.81B | 44.06 | 15.85 | 6.98% | 29.63% | 31.37% | 7.49% | 0.08 |
| INCYIncyte Corporation | 20.1B | 101.27 | 15.80 | 21.22% | 25.03% | 24.9% | 6.74% | 0.01 |
| GMABGenmab A/S | 18.13B | 29.44 | 15.36 | 30.67% | 46.8% | 114.25% | 6.6% | 0.03 |
| SNDXSyndax Pharmaceuticals, Inc. | 1.89B | 21.71 | -5.82 | -279.31% | -269.93% | 1.20 | ||
| RCUSArcus Biosciences, Inc. | 2.55B | 20.37 | -6.19 | -4.26% | -142.91% | -55.94% | 0.16 | |
| RLAYRelay Therapeutics, Inc. | 1.78B | 10.26 | -6.37 | 53.44% | -18.01% | -48.76% | 0.06 | |
| STROSutro Biopharma, Inc. | 1.74B | 20.47 | -6.92 | -59.64% | -205.18% | -234.19% | 4.57 | |
| OLMAOlema Pharmaceuticals, Inc. | 1.66B | 24.20 | -11 | -48.77% | 0.00 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 10.36M | 191K | 204K | 1.14M |
| Revenue Growth % | - | -98.16% | 6.81% | 458.33% |
| Cost of Goods Sold | 10K | 15K | 0 | 0 |
| COGS % of Revenue | 0.1% | 7.85% | - | - |
| Gross Profit | 10.35M | 176K | 204K | 1.14M |
| Gross Margin % | 99.9% | 92.15% | 100% | 100% |
| Gross Profit Growth % | - | -98.3% | 15.91% | 458.33% |
| Operating Expenses | 22.95M | 35.42M | 55.65M | 115.81M |
| OpEx % of Revenue | 221.61% | 18545.55% | 27280.88% | 10167.25% |
| Selling, General & Admin | 4.63M | 6.39M | 9.9M | 33.7M |
| SG&A % of Revenue | 44.75% | 3347.12% | 4853.43% | 2959% |
| Research & Development | 18.32M | 29.03M | 45.75M | 82.1M |
| R&D % of Revenue | 176.86% | 15198.43% | 22427.45% | 7208.25% |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -12.61M | -35.25M | -55.45M | -114.67M |
| Operating Margin % | -121.7% | -18453.4% | -27180.88% | -10067.25% |
| Operating Income Growth % | - | -179.6% | -57.32% | -106.8% |
| EBITDA | -12.6M | -35.23M | -55.43M | -114.63M |
| EBITDA Margin % | -121.61% | -18445.55% | -27172.55% | -10064.44% |
| EBITDA Growth % | - | -179.7% | -57.34% | -106.8% |
| D&A (Non-Cash Add-back) | 10K | 15K | 17K | 32K |
| EBIT | -12.39M | -35.25M | -55.45M | -114.67M |
| Net Interest Income | -451K | -1K | 6.9M | 26.62M |
| Interest Income | 0 | 0 | 6.9M | 26.62M |
| Interest Expense | 451K | 1K | 0 | 0 |
| Other Income/Expense | -233K | -197K | 6.84M | 26.63M |
| Pretax Income | -12.84M | -35.44M | -48.61M | -88.04M |
| Pretax Margin % | -123.95% | -18556.54% | -23826.96% | -7729.5% |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% | 100% |
| Net Income | -12.84M | -35.44M | -48.61M | -88.04M |
| Net Margin % | -123.95% | -18556.54% | -23826.96% | -7729.5% |
| Net Income Growth % | - | -176.06% | -37.14% | -81.12% |
| Net Income (Continuing) | -12.84M | -35.44M | -48.61M | -88.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28 | -0.66 | -1.02 | -1.41 |
| EPS Growth % | - | -135.71% | -54.55% | -38.24% |
| EPS (Basic) | -0.28 | -0.66 | -1.02 | -1.41 |
| Diluted Shares Outstanding | 66.64M | 66.64M | 66.64M | 62.5M |
| Basic Shares Outstanding | 66.64M | 66.64M | 66.64M | 62.5M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 58.41M | 147.21M | 194.12M | 754.21M |
| Cash & Short-Term Investments | 53.61M | 143.48M | 187.67M | 742M |
| Cash Only | 53.61M | 88.14M | 8.27M | 257.07M |
| Short-Term Investments | 0 | 55.34M | 179.41M | 484.93M |
| Accounts Receivable | 2K | 303K | 92K | 781K |
| Days Sales Outstanding | 0.07 | 579.03 | 164.61 | 250.28 |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 4.8M | 3.42M | 6.36M | 11.43M |
| Total Non-Current Assets | 285K | 539K | 5.18M | 587K |
| Property, Plant & Equipment | 200K | 506K | 491K | 493K |
| Fixed Asset Turnover | 51.79x | 0.38x | 0.42x | 2.31x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 85K | 33K | 4.69M | 94K |
| Total Assets | 58.69M | 147.75M | 199.3M | 754.8M |
| Asset Turnover | 0.18x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | - | 151.73% | 34.89% | 278.72% |
| Total Current Liabilities | 5.97M | 15.43M | 14.25M | 21.37M |
| Accounts Payable | 1M | 985K | 3.24M | 6.52M |
| Days Payables Outstanding | 36.61K | 23.97K | - | - |
| Short-Term Debt | 2.94M | 8.97M | 569K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.13M | 173K | 547K | 436K |
| Current Ratio | 9.78x | 9.54x | 13.62x | 35.30x |
| Quick Ratio | 9.78x | 9.54x | 13.62x | 35.30x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 12.46M | 7.14M | 257K | 52K |
| Long-Term Debt | 12.06M | 6.53M | 0 | 0 |
| Capital Lease Obligations | 50K | 257K | 244K | 52K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 351K | 352K | 13K | 0 |
| Total Liabilities | 18.44M | 22.57M | 14.51M | 21.42M |
| Total Debt | 15.13M | 15.94M | 1.03M | 238K |
| Net Debt | -38.48M | -72.2M | -7.24M | -256.83M |
| Debt / Equity | 0.38x | 0.13x | 0.01x | 0.00x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -27.95x | -35246.00x | - | - |
| Total Equity | 40.25M | 125.18M | 184.79M | 733.38M |
| Equity Growth % | - | 210.98% | 47.62% | 296.87% |
| Book Value per Share | 0.60 | 1.88 | 2.77 | 11.73 |
| Total Shareholders' Equity | 40.25M | 125.18M | 184.79M | 733.38M |
| Common Stock | 0 | 0 | 0 | 8K |
| Retained Earnings | -45.89M | -81.33M | -129.94M | -217.98M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -13.65M | -29.8M | -45.68M | -78.71M |
| Operating CF Margin % | -131.82% | -15604.19% | -22391.67% | -6910.71% |
| Operating CF Growth % | - | -118.28% | -53.26% | -72.32% |
| Net Income | -12.84M | -35.44M | -48.61M | -88.04M |
| Depreciation & Amortization | 10K | 15K | 17K | 32K |
| Stock-Based Compensation | 1.11M | 676K | 1.53M | 11.4M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 30K | 509K | -2.06M | -5.01M |
| Working Capital Changes | -1.97M | 4.44M | 3.44M | 2.91M |
| Change in Receivables | 0 | 0 | 0 | -689K |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 578K | -18K | 2.01M | 3.27M |
| Cash from Investing | -97K | -55.35M | -121.19M | -300.76M |
| Capital Expenditures | -97K | -14K | 0 | -234K |
| CapEx % of Revenue | 0.94% | 7.33% | - | 20.54% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 15.45M | 119.69M | 87M | 628.28M |
| Debt Issued (Net) | 15.2M | 0 | -16.29M | -365K |
| Equity Issued (Net) | 245K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -1.34M | -825K |
| Net Change in Cash | 1.7M | 34.54M | -79.88M | 248.8M |
| Free Cash Flow | -13.75M | -29.82M | -45.68M | -78.95M |
| FCF Margin % | -132.76% | -15611.52% | -22391.67% | -6931.26% |
| FCF Growth % | - | -116.84% | -53.19% | -72.83% |
| FCF per Share | -0.21 | -0.45 | -0.69 | -1.26 |
| FCF Conversion (FCF/Net Income) | 1.06x | 0.84x | 0.94x | 0.89x |
| Interest Paid | 0 | 0 | 376K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | -31.9% | -42.85% | -31.36% | -19.18% |
| Return on Invested Capital (ROIC) | - | -96.56% | -36.08% | -26.3% |
| Gross Margin | 99.9% | 92.15% | 100% | 100% |
| Net Margin | -123.95% | -18556.54% | -23826.96% | -7729.5% |
| Debt / Equity | 0.38x | 0.13x | 0.01x | 0.00x |
| Interest Coverage | -27.95x | -35246.00x | - | - |
| FCF Conversion | 1.06x | 0.84x | 0.94x | 0.89x |
| Revenue Growth | - | -98.16% | 6.81% | 458.33% |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics